Be Bio has raised $82 million to progress its BE-101 gene therapy for hemophilia B into a Phase I/II clinical trial, aiming for a single-infusion, durable FIX replacement therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.